Thousands of women in England with incurable breast cancer have been granted fresh hope thanks to a drug that extends life for up to three years.
The approval of the treatment Enhertu for NHS patients is a major U-turn from drug cheifs, who initially ruled it was not good value for money.
The medicine – which treats a type of breast cancer called HER2-low – has been available in Scotland since 2023, as well as 26 European nations.
A recent trade deal with the US that affects the UK’s budget for medicines, and changes to the official way value for money is measured are
To provide well-rounded coverage and a breadth of insight across various events, we rely on contributions from several staff writers, each bringing their own area of expertise to our publication.